What's Happening with These Biotech Stocks? -- OncoSec Medical, OvaScience, Pacific Biosciences of California, and Pieris Pharma
NEW YORK, March 22, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ONCS, OVAS, PACB, and PIRS which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com monitors OncoSec Medical Inc. (NASDAQ: ONCS), OvaScience Inc. (NASDAQ: OVAS), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Pieris Pharmaceuticals Inc. (NASDAQ: PIRS). These companies operate in the Biotech industry, which broadly segments into the Medical and Agricultural markets. Although Enterprising Biotechnology is also being applied to other exciting areas, like industrial production of chemicals and bioremediation, the use in these areas is still specialized and limited. All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
OncoSec Medical
On Wednesday, shares in San Diego, California headquartered OncoSec Medical Inc. saw a decline of 1.70%, ending the day at $1.73. The stock recorded a trading volume of 1.25 million shares, which was above its three months average volume of 879,190 shares. The Company's shares have advanced 3.59% over the previous three months and 34.11% over the past year. The stock is trading above its 200-day moving average by 20.43%. Moreover, shares of OncoSec Medical, which engages in developing DNA-based intratumoral immunotherapies in the US, have a Relative Strength Index (RSI) of 38.73.
On March 12th, 2018, OncoSec Medical (ONCS) announced that its manuscript, "Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer," has been published in Nature Gene Therapy. The research, led by a team of ONCS scientists, evolves the Company's current clinical EP platform to improve the therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters. Get the full research report on ONCS for free by clicking below at:
www.wallstequities.com/registration/?symbol=ONCS
OvaScience
Shares in Waltham, Massachusetts headquartered OvaScience Inc. ended the day 1.12% higher at $0.89 with a total trading volume of 165,215 shares. The stock is trading below its 50-day moving average by 12.98%. Shares of the Company, which discovers, develops, and commercializes fertility treatment options for women worldwide, have an RSI of 34.72.
On March 12th, 2018, OvaScience announced the grant of an inducement award to its newly appointed Chief Scientific Officer, James W. Lillie, Ph.D. The inducement grant to Dr. Lillie consisted of an option to purchase up to 357,057 shares of common stock. The stock options are exercisable at a price of $1.02 per share, equal to the closing price per share of the Company's common stock as reported by NASDAQ on March 06th, 2018. Today's complimentary research report on OVAS is accessible at:
www.wallstequities.com/registration/?symbol=OVAS
Pacific Biosciences of California
At the close of trading on Wednesday, shares in Menlo Park, California headquartered Pacific Biosciences of California Inc. finished 0.81% lower at $2.46 with a total trading volume of 395,917 shares. The stock is trading below its 50-day moving average by 6.38%. Shares of the Company, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have an RSI of 44.42.
On March 13th, 2018, Pacific Biosciences of California announced that the US Patent and Trademark Office has issued US Patent No. 9,910,956 (the "956 Patent"), entitled "Sequencing using concatemers of copies of sense and antisense strands." The 956 Patent was issued on March 06th, 2018, and covers novel methods for single molecule sequencing of concatemers having complementary sense and antisense regions of a nucleic acid sample, including such concatemers generated from a rolling circle amplification reaction. Register now for your free research document on PACB at:
www.wallstequities.com/registration/?symbol=PACB
Pieris Pharmaceuticals
Boston, Massachusetts headquartered Pieris Pharmaceuticals Inc.'s shares recorded a trading volume of 600,419 shares at the end of yesterday's session. The stock closed the day 1.61% higher at $7.58. The Company's shares have advanced 34.40% in the previous three months and 200.79% over the past year. The stock is trading above its 200-day moving average by 24.77%. Additionally, shares of Pieris Pharma, which discovers and develops Anticalin-based drugs, have an RSI of 47.80.
On March 09th, 2018, Pieris Pharmaceuticals announced the Company's financial results for its FY17. R&D expenses were $22.3 million, G&A expenses were $17.6 million, and net loss was $17.6 million. Cash, cash equivalents, and investments totaled $82.6 million as of December 31st, 2017.
On March 19th, 2018, research firm Jefferies initiated a 'Buy' rating on the Company's stock, with a target price of $12 per share. Click on the link below and see our free report PIRS at:
www.wallstequities.com/registration/?symbol=PIRS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Share this article